Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Major Manufacturers Covered in This Report
• 1.3 Market Segment by Type
  • 1.3.1 Global Hyperphosphatemia Drugs Market Size Growth Rate by Type (2019-2025)
  • 1.3.2 Aluminum Phosphate Binder
  • 1.3.3 Iron Phosphate Binder
  • 1.3.4 Magnesium Phosphate Binder
  • 1.3.5 Calcium Phosphate Binder
• 1.4 Market Segment by Application
  • 1.4.1 Global Hyperphosphatemia Drugs Market Share by Application (2019-2025)
  • 1.4.2 Hospitals
  • 1.4.3 Clinics
  • 1.4.4 Others
• 1.5 Study Objectives
• 1.6 Years Considered

2 Global Growth Trends

• 2.1 Global Hyperphosphatemia Drugs Market Size
  • 2.1.1 Global Hyperphosphatemia Drugs Revenue 2014-2025
  • 2.1.2 Global Hyperphosphatemia Drugs Sales 2014-2025
• 2.2 Hyperphosphatemia Drugs Growth Rate by Regions
  • 2.2.1 Global Hyperphosphatemia Drugs Sales by Regions 2014-2019
  • 2.2.2 Global Hyperphosphatemia Drugs Revenue by Regions 2014-2019
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers

3 Market Share by Manufacturers

• 3.1 Hyperphosphatemia Drugs Sales by Manufacturers
  • 3.1.1 Hyperphosphatemia Drugs Sales by Manufacturers 2014-2019
  • 3.1.2 Hyperphosphatemia Drugs Sales Market Share by Manufacturers 2014-2019
• 3.2 Revenue by Manufacturers
  • 3.2.1 Hyperphosphatemia Drugs Revenue by Manufacturers (2014-2019)
  • 3.2.2 Hyperphosphatemia Drugs Revenue Share by Manufacturers (2014-2019)
  • 3.2.3 Global Hyperphosphatemia Drugs Market Concentration Ratio (CR5 and HHI)
• 3.3 Hyperphosphatemia Drugs Price by Manufacturers
• 3.4 Key Manufacturers Hyperphosphatemia Drugs Plants/Factories Distribution and Area Served
• 3.5 Date of Key Manufacturers Enter into Hyperphosphatemia Drugs Market
• 3.6 Key Manufacturers Hyperphosphatemia Drugs Product Offered
• 3.7 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

• 4.1 Sales and Revenue for Each Type
  • 4.1.1 Aluminum Phosphate Binder Sales and Revenue (2014-2019)
  • 4.1.2 Iron Phosphate Binder Sales and Revenue (2014-2019)
  • 4.1.3 Magnesium Phosphate Binder Sales and Revenue (2014-2019)
  • 4.1.4 Calcium Phosphate Binder Sales and Revenue (2014-2019)
• 4.2 Global Hyperphosphatemia Drugs Sales Market Share by Type
• 4.3 Global Hyperphosphatemia Drugs Revenue Market Share by Type
• 4.4 Hyperphosphatemia Drugs Price by Type

5 Market Size by Application

• 5.1 Overview
• 5.2 Global Hyperphosphatemia Drugs Sales by Application

6 United States

• 6.1 United States Hyperphosphatemia Drugs Breakdown Data by Company
• 6.2 United States Hyperphosphatemia Drugs Breakdown Data by Type
• 6.3 United States Hyperphosphatemia Drugs Breakdown Data by Application

7 European Union

• 7.1 European Union Hyperphosphatemia Drugs Breakdown Data by Company
• 7.2 European Union Hyperphosphatemia Drugs Breakdown Data by Type
• 7.3 European Union Hyperphosphatemia Drugs Breakdown Data by Application

8 China

• 8.1 China Hyperphosphatemia Drugs Breakdown Data by Company
• 8.2 China Hyperphosphatemia Drugs Breakdown Data by Type
• 8.3 China Hyperphosphatemia Drugs Breakdown Data by Application

9 Rest of World

• 9.1 Rest of World Hyperphosphatemia Drugs Breakdown Data by Company
• 9.2 Rest of World Hyperphosphatemia Drugs Breakdown Data by Type
• 9.3 Rest of World Hyperphosphatemia Drugs Breakdown Data by Application
• 9.4 Rest of World Hyperphosphatemia Drugs Breakdown Data by Countries
  • 9.4.1 Rest of World Hyperphosphatemia Drugs Sales by Countries
  • 9.4.2 Rest of World Hyperphosphatemia Drugs Revenue by Countries
  • 9.4.3 Japan
  • 9.4.4 Korea
  • 9.4.5 India
  • 9.4.6 Southeast Asia

10 Company Profiles

• 10.1 Keryx Biopharmaceuticals
  • 10.1.1 Keryx Biopharmaceuticals Company Details
  • 10.1.2 Company Description and Business Overview
  • 10.1.3 Sales, Revenue and Market Share of Hyperphosphatemia Drugs
  • 10.1.4 Hyperphosphatemia Drugs Product Introduction
  • 10.1.5 Keryx Biopharmaceuticals Recent Development
• 10.2 Sanofi
  • 10.2.1 Sanofi Company Details
  • 10.2.2 Company Description and Business Overview
  • 10.2.3 Sales, Revenue and Market Share of Hyperphosphatemia Drugs
  • 10.2.4 Hyperphosphatemia Drugs Product Introduction
  • 10.2.5 Sanofi Recent Development
• 10.3 Shire
  • 10.3.1 Shire Company Details
  • 10.3.2 Company Description and Business Overview
  • 10.3.3 Sales, Revenue and Market Share of Hyperphosphatemia Drugs
  • 10.3.4 Hyperphosphatemia Drugs Product Introduction
  • 10.3.5 Shire Recent Development
• 10.4 Vifor Pharma
  • 10.4.1 Vifor Pharma Company Details
  • 10.4.2 Company Description and Business Overview
  • 10.4.3 Sales, Revenue and Market Share of Hyperphosphatemia Drugs
  • 10.4.4 Hyperphosphatemia Drugs Product Introduction
  • 10.4.5 Vifor Pharma Recent Development
• 10.5 Amgen
  • 10.5.1 Amgen Company Details
  • 10.5.2 Company Description and Business Overview
  • 10.5.3 Sales, Revenue and Market Share of Hyperphosphatemia Drugs
  • 10.5.4 Hyperphosphatemia Drugs Product Introduction
  • 10.5.5 Amgen Recent Development
• 10.6 Bayer
  • 10.6.1 Bayer Company Details
  • 10.6.2 Company Description and Business Overview
  • 10.6.3 Sales, Revenue and Market Share of Hyperphosphatemia Drugs
  • 10.6.4 Hyperphosphatemia Drugs Product Introduction
  • 10.6.5 Bayer Recent Development

11 Value Chain and Sales Channels Analysis

• 11.1 Value Chain Analysis
• 11.2 Sales Channels Analysis
  • 11.2.1 Hyperphosphatemia Drugs Sales Channels
  • 11.2.2 Hyperphosphatemia Drugs Distributors
• 11.3 Hyperphosphatemia Drugs Customers

12 Market Forecast

• 12.1 Global Hyperphosphatemia Drugs Sales and Revenue Forecast 2019-2025
• 12.2 Global Hyperphosphatemia Drugs Sales Forecast by Type
• 12.3 Global Hyperphosphatemia Drugs Sales Forecast by Application
• 12.4 Hyperphosphatemia Drugs Forecast by Regions
  • 12.4.1 Global Hyperphosphatemia Drugs Sales Forecast by Regions 2019-2025
  • 12.4.2 Global Hyperphosphatemia Drugs Revenue Forecast by Regions 2019-2025
• 12.5 United States Market Forecast
• 12.6 European Union Market Forecast
• 12.7 China Market Forecast
• 12.8 Rest of World
  • 12.8.1 Japan
  • 12.8.2 Korea
  • 12.8.3 India

13 Research Findings and Conclusion

14 Appendix

• 14.1 Research Methodology
  • 14.1.1 Methodology/Research Approach
    • 14.1.1.1 Research Programs/Design
    • 14.1.1.2 Market Size Estimation
    • 14.1.1.3 Market Breakdown and Data Triangulation
  • 14.1.2 Data Source
    • 14.1.2.1 Secondary Sources
    • 14.1.2.2 Primary Sources
• 14.2 Author Details

hosphorus is an important element for normal physiologic functions such as bone construction, nerve function, and muscle contraction. About 85% of phosphorus is stored in the bones and different tissues in the body. The excess phosphorus is eliminated from the body by the urinary system. The normal phosphate level in the blood is 3-4 mg/dL. Electrolytic disturbance resulting in high levels of phosphate in the blood causes hyperphosphatemia. Individuals with chronic kidney diseases have a decreased glomerular filtration rate and increased serum phosphate levels. The high phosphate levels in the serum lower calcium levels because of phosphate precipitation by calcium ions, leading to calcification of vascular tissues and heart diseases. Aluminum-, calcium-, magnesium-, and iron-based and aluminum-free, calcium-free phosphate binders are used to treat the condition.
Major factors driving the market include rise in prevalence of chronic diseases, high unmet medical needs, increase in the number of people undergoing dialysis, large geriatric population, and surge in public awareness worldwide. Diabetes and hypertension are the main causes of renal failure, which leads to hyperphosphatemia. However, stringent regulations by regulatory bodies such as the Food and Drug Administration (FDA), non-adherence to treatment regimens, and rise in side effects of hyperphosphatemia drugs are likely to inhibit the market. According to FDA use of hyperphosphatemia drugs for the treatment of high or low phosphorus levels in the human body is neither safe nor effective. High growth potential in untapped economies, such as India, China, South Africa, and Brazil, is expected to create lucrative opportunities for key players. Rise in geriatric population and increase in cases of osteoporosis in Asia Pacific is anticipated to drive the market. Osteoporosis is often undertreated and underdiagnosed, which is driving the hyperphosphatemia drugs market in Asia Pacific. The available calcium, lanthanum, sevelamer, and iron-based drugs for treating hyperphosphatemia are associated with certain side effects. The long-term use of calcium-based drugs such as calcium carbonate and calcium acetate can cause vascular calcification.
In 2019, the market size of Hyperphosphatemia Drugs is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Hyperphosphatemia Drugs.

This report studies the global market size of Hyperphosphatemia Drugs, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Hyperphosphatemia Drugs sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

In global market, the following companies are covered:
Keryx Biopharmaceuticals
Sanofi
Shire
Vifor Pharma
Amgen
Bayer
...

Market Segment by Product Type
Aluminum Phosphate Binder
Iron Phosphate Binder
Magnesium Phosphate Binder
Calcium Phosphate Binder

Market Segment by Application
Hospitals
Clinics
Others

Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)

The study objectives are:
To analyze and research the Hyperphosphatemia Drugs status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Hyperphosphatemia Drugs manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

In this study, the years considered to estimate the market size of Hyperphosphatemia Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025